KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment

Prostate

Volumn 74, Issue 12, 2014, Pages 1222-1230

  Dijkstra, Siebren ^a   Leyten, Gisele H J M ^a   Jannink, Sander A ^b   De Jong, Hans ^b   Mulders, Peter F A ^a   Van Oort, Inge M ^a   Schalken, Jack A ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Research and Development NovioGendix ^*  (Netherlands)

Author keywords

biomarkers; circulating tumor cells; CTC

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; DOCETAXEL; KALLIKREIN; MESSENGER RNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HYDROLYSIS; MALE; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER GENE 3; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TMPRSS2 ERG GENE; TREATMENT RESPONSE;

BIOMARKERS; CIRCULATING TUMOR CELLS; CTC;

ADULT; AGED; ANTIGENS, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KALLIKREINS; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RNA, MESSENGER; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84904701997     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22839     Document Type: Article

References (30)

1. Kirby M, Hirst C, Crawford ED,. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 2011; 65 (11): 1180-1192.
2. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI;, Investigators C-A. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995-2005.
3. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO;, Investigators T,. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010; 376 (9747): 1147-1154.
4. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF;, Investigators IS,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363 (5): 411-422.
5. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA;, Investigators TAX. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351 (15): 1502-1512.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS;, Investigators A. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-1197.
7. Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gonen M, Fleisher M, Larson SM, Sawyers CL, Scher HI,. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013; 31 (28): 3525-3530.
8. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ,. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21 (7): 1232-1237.
9. Oudard S, Banu E, Scotte F, Banu A, Medioni J, Beuzeboc P, Joly F, Ferrero JM, Goldwasser F, Andrieu JM,. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007; 18 (11): 1828-1833.
10. Shariat SF, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A,. Tumor markers in prostate cancer I: Blood-based markers. Acta Oncol 2011; 50 (Suppl 1): 61-75.
11. Armstrong AJ, Eisenberger MA, Halabi S, Oudard S, Nanus DM, Petrylak DP, Sartor AO, Scher HI,. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol 2012; 61 (3): 549-559.
12. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, Eisenberger M,. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25 (25): 3965-3970.
13. Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH;, European Organisation for Research and Treatment of Cancer; Limburgs Universitair Centrum; AstraZeneca Pharmaceuticals. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005; 23 (25): 6139-6148.
14. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14 (19): 6302-6309.
15. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G,. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10 (3): 233-239.
16. Poste G, Fidler IJ,. The pathogenesis of cancer metastasis. Nature 1980; 283 (5743): 139-146.
17. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang ZF, Rosai J,. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: Clinical implications. J Clin Oncol 1995; 13 (5): 1195-1200.
18. Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Buttyan R,. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43 (6): 765-775.
19. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB,. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59 (23): 5975-5979.
20. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM,. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310 (5748): 644-648.
21. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, Schalken J, Stenzl A, Tombal B, van der Poel H,. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011; 60 (5): 1045-1054.
22. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA,. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol 2014; 65 (3): 534-542.
23. Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI,. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol 2014; 65: 1191-1197.
24. Qiu SD, Young CY, Bilhartz DL, Prescott JL, Farrow GM, He WW, Tindall DJ,. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 1990; 144 (6): 1550-1556.
25. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Vaananen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H,. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: Concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009; 55 (4): 765-773.
26. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA,. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13 (17): 5103-5108.
27. Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM,. Noninvasive detection of TMPRS S2: ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia 2006; 8 (10): 885-888.
28. Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI,. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011; 60 (5): 897-904.
29. Jost M, Day JR, Slaughter R, Koreckij TD, Gonzales D, Kinnunen M, Groskopf J, Rittenhouse HG, Vessella RL, Reynolds MA,. Molecular assays for the detection of prostate tumor derived nucleic acids in peripheral blood. Mol Cancer 2010; 9: 174.
30. Väänänen RM, Rissanen M, Kauko O, Junnila S, Vaisanen V, Nurmi J, Alanen K, Nurmi M, Pettersson K,. Quantitative real-time RT-PCR assay for PCA3. Clin Biochem 2008; 41 (1-2): 103-108.